Share Price | Telomir Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Telomir Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Telomir Pharmaceuticals, Inc. has a market capitalization of 55.36 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Telomir Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -12.52 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 0.64 million, while total assets were reported at 1.32 million.

Q: What does Telomir Pharmaceuticals, Inc. do?

Overview: Telomir Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -2 Million (Quarterly Results - Mar 2025) Market Cap: USD 55.36 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.40 Return on Equity: 1,653.27% Price to Book: -55.36Contact Details: Registrar Address: Not available.

Q: Is Telomir Pharmaceuticals, Inc. technically bullish or bearish?

As of 18 July 2025, the technical trend for Telomir Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the moving averages indicate a bearish stance on the daily timeframe. The Bollinger Bands show a mildly bearish trend on the weekly chart. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -66.02% compared to the S&P's 12.22%, and a one-year return of -76.67% versus the S&P's 17.14%. Overall, the current technical stance is mildly bearish, with key indicators reflecting mixed signals across different timeframes.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

8.32 k

Shareholding (Dec 2025)

FII

0.62%

Held by 10 FIIs

DII

93.84%

Held by 6 DIIs

Promoter

0.00%

How big is Telomir Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Telomir Pharmaceuticals, Inc. has a market capitalization of 55.36 million, with net sales of 0.00 million and a net profit of -12.52 million over the last four quarters. The company's shareholder's funds are 0.64 million, and total assets are 1.32 million.

View full answer

What does Telomir Pharmaceuticals, Inc. do?

22-Jun-2025

Telomir Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $55.36 million. Key metrics include a debt equity ratio of 0.40 and a return on equity of 1,653.27%.

View full answer

Is Telomir Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 18, 2025, Telomir Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD, bearish daily moving averages, and significant underperformance against the S&P 500, with year-to-date and one-year returns of -66.02% and -76.67%, respectively.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 46 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.05

Return on Equity

-236.88%

Price to Book

6.60

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.75%

6 Months

-5.04%

1 Year

-51.82%

2 Years

-75.82%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Telomir Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-2.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.40

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.77%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.60

EV to EBIT

-3.16

EV to EBITDA

-3.16

EV to Capital Employed

-38.74

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-236.88%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 8 Schemes (5.53%)

Foreign Institutions

Held by 10 Foreign Institutions (0.62%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 27.59% vs 68.82% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-2.90",
          "chgp": "27.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-2.90",
          "chgp": "27.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 36.97% vs -25.95% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.50",
          "val2": "-12.20",
          "chgp": "13.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "4.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-16.50",
          "chgp": "36.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.10

-2.90

27.59%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.10

-2.90

27.59%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 27.59% vs 68.82% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.50

-12.20

13.93%

Interest

0.00

4.30

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-10.40

-16.50

36.97%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 36.97% vs -25.95% in Dec 2024

All Annual Results

Company CV

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available